Open this publication in new window or tab >>Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy. Strike Pharm AB, Uppsala, Sweden.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy. Uppsala University, Science for Life Laboratory, SciLifeLab. Strike Pharm AB, Uppsala, Sweden.
Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden..
KTH Royal Inst Technol, Sch Engn Sci Chem Biotechnol & Hlth, Dept Prot Sci, Stockholm, Sweden.;Sci Life Lab, Drug Discovery & Dev, Stockholm, Sweden..
KTH Royal Inst Technol, Sch Engn Sci Chem Biotechnol & Hlth, Dept Prot Sci, Stockholm, Sweden.;Sci Life Lab, Drug Discovery & Dev, Stockholm, Sweden..
KTH Royal Inst Technol, Sch Engn Sci Chem Biotechnol & Hlth, Dept Prot Sci, Stockholm, Sweden.;Sci Life Lab, Drug Discovery & Dev, Stockholm, Sweden..
KTH Royal Inst Technol, Sch Engn Sci Chem Biotechnol & Hlth, Dept Prot Sci, Stockholm, Sweden.;Sci Life Lab, Drug Discovery & Dev, Stockholm, Sweden..
KTH Royal Inst Technol, Sch Engn Sci Chem Biotechnol & Hlth, Dept Prot Sci, Stockholm, Sweden.;Sci Life Lab, Drug Discovery & Dev, Stockholm, Sweden..
Strike Pharm AB, Uppsala, Sweden.;Scicross AB, Skövde, Sweden..
KTH Royal Inst Technol, Sch Engn Sci Chem Biotechnol & Hlth, Dept Prot Sci, Stockholm, Sweden.;Strike Pharm AB, Uppsala, Sweden..
Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy. Strike Pharm AB, Uppsala, Sweden.
Show others...
2024 (English)In: Nature Communications, E-ISSN 2041-1723, Vol. 15, no 1, article id 9542Article in journal (Refereed) Published
Abstract [en]
Current antibody-based immunotherapy depends on tumor antigen shedding for proper T cell priming. Here we select a novel human CD40 agonistic drug candidate and generate a bispecific antibody, herein named BiA9*2_HF, that allows for rapid antibody-peptide conjugate formation. The format is designed to facilitate peptide antigen delivery to CD40 expressing cells combined with simultaneous CD40 agonistic activity. In vivo, the selected bispecific antibody BiA9*2_HF loaded with peptide cargos induces improved antigen-specific proliferation of CD8+ (10-15 fold) and CD4+ T cells (2-7 fold) over control in draining lymph nodes. In both virus-induced and neoantigen-based mouse tumor models, BiA9*2_HF demonstrates therapeutic efficacy and elevated safety profile, with complete tumor clearance, as well as measured abscopal impact on tumor growth. The BiA9*2_HF drug candidate can thus be utilized to tailor immunotherapeutics for cancer patients.
Place, publisher, year, edition, pages
Springer Nature, 2024
National Category
Immunology in the medical area Cancer and Oncology Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
urn:nbn:se:uu:diva-543865 (URN)10.1038/s41467-024-53839-5 (DOI)001348514000014 ()39500897 (PubMedID)2-s2.0-85208602407 (Scopus ID)
Funder
Uppsala UniversityVinnova, 2021-02640Vinnova, 2017-02105Vinnova, 2016-05181Knut and Alice Wallenberg Foundation, 2020.0182Swedish Cancer Society, 22 2219 PjScience for Life Laboratory, SciLifeLabSwedish Society for Medical Research (SSMF), S15-0065Vinnova, 2019-00048
Note
De två första författarna delar förstaförfattarskapet
De två sista författarna delar sistaförfattarskapet
2024-11-282024-11-282025-04-05Bibliographically approved